STOCK TITAN
  1. Home
  2. Sec-filings
  3. CNTX
  4. [Form 4] Context Therapeutics Inc. Insider Trading Activity

Context Therapeutics (CNTX) director Linda West awarded 45K stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Context Therapeutics director Linda West received a new stock option grant as part of her compensation. She was awarded options to acquire 45,000 shares of common stock at an exercise price of $0.576 per share, expiring on June 23, 2036.

The option vests and becomes exercisable on the earlier of June 24, 2027, or the company’s 2027 annual meeting of stockholders, and is subject to her continued service with Context Therapeutics. After this grant, she holds stock options for 45,000 underlying shares directly.

Positive

  • None.

Negative

  • None.
Insider West Linda
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 45,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 45,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 45,000 options Stock Option (right to buy) grant on June 24, 2026
Exercise price $0.576 per share Exercise price for the granted stock options
Underlying shares 45,000 shares Common stock underlying the options
Total options after grant 45,000 options Total derivative holdings following the transaction
Option expiration June 23, 2036 Expiration date of the stock options
Vesting date trigger June 24, 2027 Earlier of this date or 2027 annual meeting, subject to service
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 0.5760"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual meeting of stockholders financial
"the Issuer's 2027 annual meeting of stockholders, subject to continued service"
continued service financial
"subject to continued service with the Issuer"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
West Linda
(Last)(First)(Middle)
2001 MARKET STREET
SUITE 3915, UNIT #15
(Street)
PHILADELPHIA PENNSYLVANIA 19103
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Context Therapeutics Inc. [ CNTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$0.57606/24/2026A45,000 (1)06/23/2036Common Stock45,000$045,000D
Explanation of Responses:
1. The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.
Remarks:
/s/ Alex Levit, Attorney-in-Fact06/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Context Therapeutics (CNTX) director Linda West receive in this Form 4?

Linda West received a grant of stock options for 45,000 shares of Context Therapeutics common stock. These options are a compensation award and give her the right to buy shares at a fixed exercise price in the future, subject to vesting conditions.

What is the exercise price of Linda West’s Context Therapeutics (CNTX) stock options?

The stock options granted to Linda West have an exercise price of $0.576 per share. This is the price she must pay to purchase each share if she exercises the options after they vest and before they expire.

When do Linda West’s Context Therapeutics (CNTX) stock options vest?

The options vest on the earlier of June 24, 2027, or Context Therapeutics’ 2027 annual meeting of stockholders. Vesting is also conditioned on Linda West’s continued service with the company through that date or meeting, as described in the filing footnote.

When do Linda West’s Context Therapeutics (CNTX) stock options expire?

The granted stock options expire on June 23, 2036, if not exercised. After that date, Linda West will no longer be able to use these options to buy Context Therapeutics common stock, even if they have vested and remain unexercised.

How many Context Therapeutics (CNTX) options does Linda West hold after this grant?

Following this grant, Linda West holds stock options covering 45,000 shares of Context Therapeutics common stock. The Form 4 shows this as her total derivative holdings related to this award after the transaction, all held as a direct ownership position.